Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up more than 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Sagent Pharmaceuticals (SGNT) Misses Q4 EPS Views; Guides FY16 Revenue Below Expectations
February 16, 2016 7:33 AM ESTSagent Pharmaceuticals (NASDAQ: SGNT) reported Q4 EPS of ($0.55), $0.53 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $83.1 million versus the consensus estimate of $78.13 million.
GUIDANCE:
Sagent Pharmaceuticals sees FY2016 revenue of $325 - $365 million, versus the consensus of... More
